62473-92-1

Basic information

• Product Name: 6-BROMOSACCHARINE
• Synonyms: RARECHEM AM UH V180;6-BROMOSACCHARINE;6-Bromobenzo[d]isothiazol-3(2H)-one 1,1-dioxide;6-bromosaccharin
• CAS NO: 62473-92-1
• Molecular Formula: C₇H₄BrNO₃S
• Molecular Weight: 262.08
• Mol File: 62473-92-1.mol
• Article Data: 13

Chemical Properties

• Appearance: /
• Density: 1.958±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 1.15±0.30(Predicted)
• CAS DataBase Reference: 6-BROMOSACCHARINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMOSACCHARINE(62473-92-1)
• EPA Substance Registry System: 6-BROMOSACCHARINE(62473-92-1)

Safety Data

• Hazardous Substances Data: 62473-92-1(Hazardous Substances Data)

Usage

General Description

6-Bromosaccharin is a chemical compound derived from saccharin, an artificial sweetener. It is a halogenated derivative of saccharin and is used as a pharmaceutical intermediate in the production of various drugs. 6-Bromosaccharin has a wide range of applications in the pharmaceutical industry, including as an intermediate in the synthesis of anti-inflammatory and anti-neoplastic drugs. It is also known for its potential anti-cancer properties and has been studied for its antineoplastic activity. Additionally, it has been found to have antimicrobial and antifungal properties, making it useful in the development of new antimicrobial agents.

Upstream product

• 56919-16-5 5-bromo-2-methylbenzene-1-sulfonamide 
• 135484-83-2 2-amino-4-bromo-benzoic acid methyl ester 
• 106-38-7 para-bromotoluene 
• 69321-56-8 5-bromo-2-methyl-benzene-sulfonyl chloride 
• 1242134-19-5 4-bromo-2-sulfamoylbenzoic acid 
• 52727-57-8 5-bromo-2-aminobenzoic acid methyl ester 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 

Downstream Products

• 154607-01-9 4-bromo-2-chlorobenzonitrile 
• 612537-88-9 5-bromo-2-cyano-N-(5-isopropyl-4-methyl-3H-thiazol-2-ylidene)-benzenesulfonamide 
• 1310719-66-4 C₂₈H₃₀BrN₅O₅S 
• 1310719-85-7 C₂₉H₃₀N₆O₅S 
• 1414888-02-0 2-benzyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide 
• 1414888-03-1 (2-benzyl-1,1-dioxido-3-oxo-2,3-dihydrobenzo[d]isothiazol-6-yl)boronic acid 
• 1414888-04-2 6,6'-((1,1' : 3',1''-terphenyl)-3,3''-diylbis(methylene))bis(2-benzylbenzo[d]isothiazol-3(2H)-one) 1,1-dioxide 
• 1414888-01-9 2-benzyl-6-bromobenzo[d]isothiazol-3(2H)-one 1,1-dioxide 
• 1341040-15-0 6-bromo-2,3-dihydrobenzo[d]isothiazole 1,1-dioxide 

Relevant articles and documents

Preparation method and medical application of benzisothiazole and benzothiophene

The invention discloses a preparation method and medical application of benzisothiazole and benzothiophene, and telates to the field of pharmaceutical chemistry. According to the invention, benzisothiazole and benzothiophene are the first type of HIF-2 agonists; compared with a compound M1001 found by the applicant in the earlier stage, the invention has better HIF-2 agonist activity, and has remarkable enhancement activity on expression of mRNA and protein of EPO, VGEF, Glut1, NDRG1 and the like at the downstream of HIF-2, so that the invention can be used for preparing drugs for treating and/or preventing chronic kidney diseases/chronic renal anemia, dyslipidemia and high cholesterol caused by abnormal expression of HIF-2; and the method has a good industrialization prospect.

A scaffold replacement approach towards new sirtuin 2 inhibitors

Sirtuins (SIRT1–SIRT7) are an evolutionary conserved family of NAD+-dependent protein deacylases regulating the acylation state of ε-N-lysine residues of proteins thereby controlling key biological processes. Numerous studies have found association of the aberrant enzymatic activity of SIRTs with various diseases like diabetes, cancer and neurodegenerative disorders. Previously, we have shown that substituted 2-alkyl-chroman-4-one/chromone derivatives can serve as selective inhibitors of SIRT2 possessing an antiproliferative effect in two human cancer cell lines. In this study, we have explored the bioisosteric replacement of the chroman-4-one/chromone core structure with different less lipophilic bicyclic scaffolds to overcome problems associated to poor physiochemical properties due to a highly lipophilic substitution pattern required for achieve a good inhibitory effect. Various new derivatives based on the quinolin-4(1H)-one scaffold, bicyclic secondary sulfonamides or saccharins were synthesized and evaluated for their SIRT inhibitory effect. Among the evaluated scaffolds, the benzothiadiazine-1,1-dioxide-based compounds showed the highest SIRT2 inhibitory activity. Molecular modeling studies gave insight into the binding mode of the new scaffold-replacement analogues.

Novel compounds that are inhibitors of YAP/TAZ-TEAD interaction and their use in the treatment of malignant mesothelioma

These compounds are useful as inhibitors of the YAP/TAZ-TEAD interaction.